JP2023061966A - 温度に影響されない膜材料とそれを含む分析物センサー - Google Patents
温度に影響されない膜材料とそれを含む分析物センサー Download PDFInfo
- Publication number
- JP2023061966A JP2023061966A JP2023010402A JP2023010402A JP2023061966A JP 2023061966 A JP2023061966 A JP 2023061966A JP 2023010402 A JP2023010402 A JP 2023010402A JP 2023010402 A JP2023010402 A JP 2023010402A JP 2023061966 A JP2023061966 A JP 2023061966A
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- amine
- film composition
- side chains
- polymer film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 104
- 239000012528 membrane Substances 0.000 title abstract description 33
- 239000000463 material Substances 0.000 title abstract description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 223
- 229920000642 polymer Polymers 0.000 claims abstract description 163
- 229920000570 polyether Polymers 0.000 claims abstract description 97
- 239000004721 Polyphenylene oxide Substances 0.000 claims abstract description 96
- 239000000203 mixture Substances 0.000 claims abstract description 84
- 230000035699 permeability Effects 0.000 claims abstract description 14
- 229920006254 polymer film Polymers 0.000 claims description 51
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 34
- 229920001451 polypropylene glycol Polymers 0.000 claims description 31
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 20
- 239000008103 glucose Substances 0.000 claims description 20
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 229920001577 copolymer Polymers 0.000 claims description 15
- 229920005597 polymer membrane Polymers 0.000 claims description 9
- 229920002717 polyvinylpyridine Polymers 0.000 claims description 9
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 9
- 239000003431 cross linking reagent Substances 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 claims description 5
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 239000004971 Cross linker Substances 0.000 description 33
- 125000000217 alkyl group Chemical group 0.000 description 24
- 239000002243 precursor Substances 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 238000012544 monitoring process Methods 0.000 description 15
- 239000002202 Polyethylene glycol Substances 0.000 description 13
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 125000001033 ether group Chemical group 0.000 description 11
- 231100000135 cytotoxicity Toxicity 0.000 description 10
- 230000003013 cytotoxicity Effects 0.000 description 10
- 125000003827 glycol group Chemical group 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 125000006850 spacer group Chemical group 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical class C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 150000001412 amines Chemical group 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 150000002118 epoxides Chemical group 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- CLWRFNUKIFTVHQ-UHFFFAOYSA-N [N].C1=CC=NC=C1 Chemical group [N].C1=CC=NC=C1 CLWRFNUKIFTVHQ-UHFFFAOYSA-N 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 238000004891 communication Methods 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- -1 for example Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000007794 irritation Effects 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 5
- 206010018910 Haemolysis Diseases 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 230000008588 hemolysis Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 150000003440 styrenes Chemical class 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 150000003857 carboxamides Chemical class 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 150000004820 halides Chemical group 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 150000005375 primary alkyl halides Chemical class 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 150000001733 carboxylic acid esters Chemical class 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 229920000140 heteropolymer Polymers 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 231100000299 mutagenicity Toxicity 0.000 description 2
- 230000007886 mutagenicity Effects 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000027756 respiratory electron transport chain Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- GMPYNOTVKNXELU-UHFFFAOYSA-N 1-bromoethanesulfonic acid Chemical compound CC(Br)S(O)(=O)=O GMPYNOTVKNXELU-UHFFFAOYSA-N 0.000 description 1
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 1
- MLMGJTAJUDSUKA-UHFFFAOYSA-N 2-ethenyl-1h-imidazole Chemical compound C=CC1=NC=CN1 MLMGJTAJUDSUKA-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- 238000010953 Ames test Methods 0.000 description 1
- 231100000039 Ames test Toxicity 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 231100000899 acute systemic toxicity Toxicity 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- HMPHJJBZKIZRHG-UHFFFAOYSA-N chloromethanesulfonic acid Chemical compound OS(=O)(=O)CCl HMPHJJBZKIZRHG-UHFFFAOYSA-N 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 229920005565 cyclic polymer Polymers 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 150000005052 perimidines Chemical class 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000005053 phenanthridines Chemical class 0.000 description 1
- 150000005041 phenanthrolines Chemical class 0.000 description 1
- 150000002988 phenazines Chemical class 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003195 pteridines Chemical class 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 150000003252 quinoxalines Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 231100000195 subchronic toxicity Toxicity 0.000 description 1
- 230000007666 subchronic toxicity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 150000008053 sultones Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 150000004867 thiadiazoles Chemical class 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L39/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions of derivatives of such polymers
- C08L39/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
- C08L39/08—Homopolymers or copolymers of vinyl-pyridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14503—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
- C08G65/33317—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
- C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
- C08G81/024—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G
- C08G81/025—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G containing polyether sequences
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/18—Manufacture of films or sheets
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L39/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions of derivatives of such polymers
- C08L39/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
- A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
- A61B5/686—Permanently implanted devices, e.g. pacemakers, other stimulators, biochips
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2339/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Derivatives of such polymers
- C08J2339/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
- C08J2339/08—Homopolymers or copolymers of vinyl-pyridine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Manufacturing & Machinery (AREA)
- Emergency Medicine (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Polyethers (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Abstract
Description
開示された主題は、本開示の範囲から逸脱することなく、形態及び機能においてかなりの修正、変更、組み合わせ、及び同等物が可能である。
様々な実施形態によれば、アミンを含まないポリエーテルアームは、複素環式ポリマーの1つ以上の側鎖の複素環の少なくとも一部内のヘテロ原子を介して、本明細書に開示されるポリマー膜組成物のポリマー骨格に結合し得る。代替の実施形態は、アミンを含まないポリエーテルアームが、1つ以上の側鎖の複素環の少なくとも一部の炭素原子を介して、及び/又はポリマー骨格の任意選択で置換されたフェニル基の炭素原子を介してポリマー骨格に結合するものを含み得る。より詳細な実施形態では、アミンを含まないポリエーテルアームは、1つ以上の側鎖内の複素環芳香族窒素原子又はヘテロ芳香族窒素原子を介してポリマー主鎖に結合することができる。例えば、ポリマー主鎖がポリビニルピリジン又はそのコポリマーである場合、アミンを含まないポリエーテルアームは、ピリジン窒素原子を介して側鎖に付加され得る。アミンを含まないポリエーテルアーム又は架橋剤で官能化すると、ピリジン窒素原子は四級化された形になる。
d=a-c1-c2(数式1)
となる架橋剤である。したがって、複素環式ポリマーのヘテロ芳香族(ピリジン)環は、本開示の様々なポリマー膜組成物の実施形態において、任意の組み合わせ又はパターンでZ1及びZ2で官能化され得る。すなわち、化学式2~7によって定義される繰り返し単位は、本開示のポリマー膜組成物に組み込むのに適した複素環式ポリマーを定義する際に、互いに任意の組み合わせで存在し得る。
A.ポリマー膜組成物 ポリマー膜組成物は、以下を含む:複素環を含む1つ以上の側鎖を含むポリマー骨格;アミンを含まないポリエーテルアームであって、アルキルスペーサー又はヒドロキシ官能化アルキルスペーサーを介して、1つ以上の側鎖の少なくとも一部の複素環に付加されている、アミンを含まないポリエーテルアーム。
要素1:ポリマー主鎖がポリビニルピリジン又はポリビニルイミダゾールを含む。
要素3:アミンを含まないポリエーテルアームは、少なくとも1つのポリエチレンオキシドブロック及び少なくとも1つのポリプロピレンオキシドブロックを含み、アミンを含まないポリエーテルアームは、ポリマー主鎖の側鎖の複素環式又はヘテロ芳香族窒素原子に結合している。
要素5:ここで、xは約8~約16の範囲であり、yは約10~約32の範囲であり、zは約10~約20の範囲である。
要素7:ここで、(x+z):yの比は少なくとも約1.7:1である。
要素8:ここで、(x+z):yの比は、約1.7:1~約5:1の範囲である。
要素10:ここで、ポリマー膜組成物は、1つ以上の側鎖の少なくとも一部に付加され、第1のポリマー骨格を第2のポリマー骨格に結合させる架橋剤をさらに含む。
要素12:ここで、ポリマー膜組成物は、アルキルスペーサー又はヒドロキシ官能化アルキルスペーサーを介して、1つ以上の側鎖の少なくとも一部の複素環に付加された、アミンを含まないポリエチレンオキシドアームをさらに含む。
要素1,2;要素1,3;要素1,4;要素1,4,5;要素1,4,6;要素1,4,5,6;要素1,4,7;1,4,5,7;要素1,4,8;要素1,4,5,8;要素1,9;要素1,10;要素1,12;要素1,9,10;要素2,3;要素2,4;要素2,4,5;要素2,4,6;要素2,4,5,6;要素2,4,7;要素2,4,5,7;要素2,4,8;要素2,4,5,8;要素2,9;要素2,10;要素2,9,10;要素3,4;要素3,4,5;要素3,4,6;要素3,4,5,6;要素3,4,7;要素3,4,5,7;要素3,4,8;要素3,4,5,9;要素3,9;要素3,103,9,10;要素4,5;要素4,6;要素4,5,6;要素4,7;要素4,5,7;要素4,8;要素4,5,8;要素4,9;要素4,10;要素4,9,10;要素4,12;要素9,10;要素10,12;要素11,12と組み合わせた、Aの組成物。要素1,2;要素1,3;要素1,4;要素1,4,5;要素1,4,6;要素1,4,5,6;要素1,4,7;1,4,5,7;要素1,4,8;要素1,4,5,8;要素1,9;要素1,10;要素1,12;要素1,9,10;要素2,3;要素2,4;要素2,4,5;要素2,4,6;要素2,4,5,6;要素2,4,7;要素2,4,5,7;要素2,4,8;要素2,4,5,8;要素2,9;要素2,10;要素2,9,10;要素3,4;要素3,4,5;要素3,4,6;要素3,4,5,6;要素3,4,7;要素3,4,5,7;要素3,4,8;要素3,4,5,9;要素3,9;要素3,103,9,10;要素4,5;要素4,6;要素4,5,6;要素4,7;要素4,5,7;要素4,8;要素4,5,8;要素4,9;要素4,10;要素4,9,10;要素4,12;要素9,10;要素10,12;要素11,12と組み合わせた、Bの分析物センサーであって、さらに要素11と組み合わせることも可能であるセンサー。Cの組成物は、Aに適用可能な任意の要素と組み合わせて使用することができる。
実施例1:温度バラつき。化学式12(w=1、x=14、y=12、z=18)に対応する構造を持つ、アミンを含まないポリエーテルアームを有した、スチレンとのポリビニルピリジンコポリマーを、グルコース応答性センサーにコーティングした。次に、コーティングされたセンサーを固定濃度のグルコース溶液にさらし、センサーの応答をある範囲の温度で測定した。図4は、17℃~42℃の温度範囲にわたるセンサー応答データのプロットを示している。図4に示すように、センサー応答は、人間の正常な生理学的温度を含む温度範囲の有意の部分にわたって最小限のバラつきを示した。応答バラつきの開始が観察され始めた温度(すなわち、37℃を超える)でさえ、図5の棒グラフに示されるように、応答バラつきは5℃測定間隔の全体において、2%未満であった。
溶血。溶血研究は、ASTM F756で指定されている抽出法(リン酸緩衝生理食塩水)を使用して、エントリー3のポリマーで実施された。抽出物と陰性対照の間で溶血に違いはなかったので、エントリー3のポリマーは非溶血性であり、溶血指数は2以下だったことを意味している。
単回投与全身刺激性試験。エントリー3のポリマーの抽出物を静脈内又は腹腔内に注射した。観察期間中、対照と比較して毒性の兆候は見られなかった。
皮内刺激性試験。エントリー3のポリマーの抽出物の皮内刺激性試験では、72時間の観察期間にわたって、ビヒクル対照と比較して異常な臨床徴候は生じなかった。対照と比較して計算された紅斑及び浮腫のスコアは1未満だった(ほとんど知覚できない紅斑又は浮腫はない)。
特に明記しない限り、本明細書及び関連する特許請求の範囲において数量などを表すすべての数字は、すべての場合において「約」という用語によって変更されるものとして理解されるべきである。したがって、反対に示されない限り、以下の明細書及び添付の特許請求の範囲に示される数値パラメーターは、本発明の実施形態によって得られることが求められる所望の特性に応じて変動し得る近似値である。少なくとも、そして均等論の適用をクレームの範囲に限定しようとするものではなく、各数値パラメーターは少なくとも、報告された有効桁数を考慮して、通常の丸め手法を適用することによって解釈されるべきである。
様々なシステム、ツール、及び方法は、様々なコンポーネント又はステップを「含む」という観点から本明細書で説明されるが、システム、ツール、及び方法はまた、様々なコンポーネント及びステップから「本質的に構成される」又は「構成される」ことができる。
Claims (27)
- 複素環を含む1つ以上の側鎖を含むポリマー骨格と、
アルキルスペーサー又はヒドロキシ官能化アルキルスペーサーを介して、1つ以上の側鎖の少なくとも一部の前記複素環に付加されたアミンを含まないポリエーテルアームとを含んでなる、ポリマー膜組成物。 - 前記ポリマー主鎖が、ポリビニルピリジン又はポリビニルイミダゾールを含む、請求項1に記載のポリマー膜組成物。
- 前記ポリマー主鎖がビニルピリジンとスチレンのコポリマーを含む、請求項2に記載のポリマー膜組成物。
- 前記アミンを含まないポリエーテルアームが、少なくとも1つのポリエチレンオキシドブロックと少なくとも1つのポリプロピレンオキシドブロックとを含み、前記アミンを含まないポリエーテルアームが、ポリマー骨格の側鎖中の複素環式又はヘテロ芳香族窒素原子に結合している、請求項1に記載のポリマー膜組成物。
- xが約8~約16の範囲にあり、yが約10~約32の範囲にあり、zが約10~約20の範囲にある、請求項5に記載のポリマー膜組成物。
- x≦zである、請求項5に記載のポリマー膜組成物。
- (x+z):yの比が少なくとも約1.7:1である、請求項5に記載のポリマー膜組成物。
- (x+z):yの比が約1.7:1~約5:1の範囲にある、請求項5に記載のポリマー膜組成物。
- 1つ以上の側鎖の少なくとも一部に付加されたスルホネート含有アームをさらに含む、請求項1に記載のポリマー膜組成物。
- アルキルスペーサー又はヒドロキシ官能化アルキルスペーサーを介して、1つ以上の側鎖の少なくとも一部の複素環に付加されたアミンを含まないポリエチレンオキシドアームをさらに含む、請求項1に記載のポリマー膜組成物。
- 1つ以上の側鎖の少なくとも一部に付加され、第1のポリマー骨格を第2のポリマー骨格に結合させる架橋剤をさらに含む、請求項1に記載のポリマー膜組成物。
- 前記ポリマー膜組成物がISO10993-1規格を満たし、又はこの規格超える、請求項1に記載のポリマー膜組成物。
- 感知領域と、
前記感知領域を覆うポリマー膜組成物とを含む分析物センサーにおいて、
前記ポリマー膜組成物は、複素環を含む1つ以上の側鎖を含むポリマー主鎖と、アルキルスペーサー又はヒドロキシ官能化アルキルスペーサーを介して、前記1つ以上の側鎖の少なくとも一部の複素環に付加されたアミンを含まないポリエーテルアームを含む、分析物センサー。 - 前記感知領域が酵素を含む、請求項14に記載の分析物センサー。
- 前記ポリマー主鎖が、ポリビニルピリジン又はポリビニルイミダゾールを含む、請求項14に記載の分析物センサー。
- 前記ポリマー主鎖がビニルピリジンとスチレンのコポリマーを含む、請求項16に記載の分析物センサー。
- 前記アミンを含まないポリエーテルアームが、少なくとも1つのポリエチレンオキシドブロック及び少なくとも1つのポリプロピレンオキシドブロックを含み、アミンを含まないポリエーテルアームが、前記ポリマー骨格の前記側鎖の複素環式又はヘテロ芳香族窒素原子に結合している、請求項14に記載の分析物センサー。
- 前記xは約8~約16の範囲にあり、前記yは約10~約32の範囲にあり、前記zは約1~約20の範囲にある、請求項19に記載の分析物センサー。
- x≦zである、請求項19に記載の分析物センサー。
- (x+z):yの比が少なくとも約1.7:1である、請求項19に記載の分析物センサー。
- (x+z):yの比が約1.7:1~約5:1の範囲である、請求項19に記載の分析物センサー。
- 1つ以上の側鎖の少なくとも一部に付加されたスルホネート含有アームをさらに含む、請求項14に記載の分析物センサー。
- アルキルスペーサー又はヒドロキシ官能化アルキルスペーサーを介して、1つ以上の側鎖の少なくとも一部の複素環に付加されたアミンを含まないポリエチレンオキシドアームをさらに含む、請求項14に記載の分析物センサー。
- 1つ以上の側鎖の少なくとも一部に付加され、第1のポリマー骨格を第2のポリマー骨格に結合させる架橋剤をさらに含む、請求項14に記載の分析物センサー。
- 約15℃~約45℃の温度範囲にわたって少なくともグルコース透過性に対して温度非感受性であり、ISO10993-1規格を満たすか又は超えるポリマー膜組成物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862684438P | 2018-06-13 | 2018-06-13 | |
US62/684,438 | 2018-06-13 | ||
PCT/US2019/036469 WO2019241192A1 (en) | 2018-06-13 | 2019-06-11 | Temperature-insensitive membrane materials and analyte sensors containing the same |
JP2020566888A JP7280288B2 (ja) | 2018-06-13 | 2019-06-11 | 温度に影響されない膜材料とそれを含む分析物センサー |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020566888A Division JP7280288B2 (ja) | 2018-06-13 | 2019-06-11 | 温度に影響されない膜材料とそれを含む分析物センサー |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023061966A true JP2023061966A (ja) | 2023-05-02 |
JP2023061966A5 JP2023061966A5 (ja) | 2023-06-21 |
Family
ID=67138054
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020566888A Active JP7280288B2 (ja) | 2018-06-13 | 2019-06-11 | 温度に影響されない膜材料とそれを含む分析物センサー |
JP2023010402A Pending JP2023061966A (ja) | 2018-06-13 | 2023-01-26 | 温度に影響されない膜材料とそれを含む分析物センサー |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020566888A Active JP7280288B2 (ja) | 2018-06-13 | 2019-06-11 | 温度に影響されない膜材料とそれを含む分析物センサー |
Country Status (7)
Country | Link |
---|---|
US (2) | US11667758B2 (ja) |
EP (1) | EP3806739A1 (ja) |
JP (2) | JP7280288B2 (ja) |
CN (1) | CN112654290A (ja) |
AU (2) | AU2019284481B2 (ja) |
CA (1) | CA3101617A1 (ja) |
WO (1) | WO2019241192A1 (ja) |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997049387A1 (en) | 1996-06-27 | 1997-12-31 | G.D. Searle And Co. | Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications |
US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
US6932894B2 (en) | 2001-05-15 | 2005-08-23 | Therasense, Inc. | Biosensor membranes composed of polymers containing heterocyclic nitrogens |
EP1959998B1 (de) * | 2005-12-09 | 2010-03-03 | Basf Se | Copolymere auf basis von polyalkylenoxid-modifizierten n-vinyllactam-copolymeren |
DE102007038449A1 (de) * | 2007-08-14 | 2009-02-19 | Bayer Technology Services Gmbh | Verfahren zur Herstellung von Thiophenoligomeren |
FR2920777B1 (fr) * | 2007-09-11 | 2009-11-27 | Centre Nat Rech Scient | Procede de preparation de derives (poly(oxyde d'ethylene) poly(oxyde de propylene) thermosensibles utiles pour fonctionnaliser le chitosane |
EP2161020A1 (en) * | 2008-09-09 | 2010-03-10 | Koninklijke Philips Electronics N.V. | Chelating amphiphilic polymers |
CN103037755A (zh) * | 2010-07-28 | 2013-04-10 | 雅培糖尿病护理股份有限公司 | 具有温度不敏感膜的分析物传感器 |
US9380965B2 (en) | 2011-05-20 | 2016-07-05 | Abbott Diabetes Care Inc. | Analyte sensors having a membrane with low temperature sensitivity |
US9535027B2 (en) * | 2012-07-25 | 2017-01-03 | Abbott Diabetes Care Inc. | Analyte sensors and methods of using same |
US9441258B2 (en) * | 2013-06-28 | 2016-09-13 | Verily Life Sciences LLP | Enzyme immobilization by crosslinking |
FR3011550B1 (fr) * | 2013-10-07 | 2016-11-18 | Arkema France | Copolymere a blocs polyamide et a bloc polyether |
WO2016025064A1 (en) * | 2014-08-15 | 2016-02-18 | Abbott Diabetes Care Inc. | Temperature insensitive in vivo analyte devices, methods and systems |
US9617502B2 (en) * | 2014-09-15 | 2017-04-11 | The Procter & Gamble Company | Detergent compositions containing salts of polyetheramines and polymeric acid |
WO2016049388A1 (en) * | 2014-09-25 | 2016-03-31 | The Procter & Gamble Company | Fabric care compositions containing a polyetheramine |
WO2016071386A1 (en) * | 2014-11-05 | 2016-05-12 | Basf Se | Novel polymer compositions and use of these polymer compositions as dispersants |
-
2019
- 2019-06-11 WO PCT/US2019/036469 patent/WO2019241192A1/en unknown
- 2019-06-11 JP JP2020566888A patent/JP7280288B2/ja active Active
- 2019-06-11 AU AU2019284481A patent/AU2019284481B2/en active Active
- 2019-06-11 CA CA3101617A patent/CA3101617A1/en active Pending
- 2019-06-11 CN CN201980039279.5A patent/CN112654290A/zh active Pending
- 2019-06-11 US US16/474,790 patent/US11667758B2/en active Active
- 2019-06-11 EP EP19734987.1A patent/EP3806739A1/en active Pending
-
2022
- 2022-10-13 AU AU2022252770A patent/AU2022252770A1/en active Pending
-
2023
- 2023-01-26 JP JP2023010402A patent/JP2023061966A/ja active Pending
- 2023-04-21 US US18/304,581 patent/US20230365758A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230365758A1 (en) | 2023-11-16 |
JP7280288B2 (ja) | 2023-05-23 |
US11667758B2 (en) | 2023-06-06 |
EP3806739A1 (en) | 2021-04-21 |
US20220002498A1 (en) | 2022-01-06 |
AU2019284481A1 (en) | 2020-12-03 |
AU2022252770A1 (en) | 2022-11-03 |
JP2021525304A (ja) | 2021-09-24 |
CN112654290A (zh) | 2021-04-13 |
CA3101617A1 (en) | 2019-12-19 |
WO2019241192A1 (en) | 2019-12-19 |
AU2019284481B2 (en) | 2022-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8444834B2 (en) | Redox polymers for use in analyte monitoring | |
JP5324473B2 (ja) | 複素環式窒素含有ポリマーで被覆された検体監視装置 | |
US8268143B2 (en) | Oxygen-effect free analyte sensor | |
US9775544B2 (en) | Analyte sensors having a membrane with low temperature sensitivity | |
US9885073B2 (en) | Cationic polymer based wired enzyme formulations for use in analyte sensors | |
CN111989042A (zh) | 乳酸传感器及相关方法 | |
AU2020414719B2 (en) | Analyte sensors and sensing methods featuring low-potential detection | |
CA2802867A1 (en) | Analyte sensors having temperature independent membranes | |
US20120138484A1 (en) | Analyte Sensors Comprising Thickeners, Enzyme Stabilizers and Osmium Boronates | |
EP3423591A1 (en) | Nad(p)-dependent responsive enzymes, electrodes and sensors, and methods for making and using the same | |
JP2023059915A (ja) | pH測定のセンサ及び方法 | |
JP7280288B2 (ja) | 温度に影響されない膜材料とそれを含む分析物センサー | |
JP2022518568A (ja) | クレアチニンを検出するための分析物センサ及び検出方法 | |
JP2023531192A (ja) | 干渉信号を低減するための縮小面積作用電極を特徴とする検体センサ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230222 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230613 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240311 |